Document Classification

Section Type: RESULTS

Text: In exploratory analyses, median progression-free survival was 5. 2 months (95 % CI, 4. 4 to 5. 6 months) for (ziv -) aflibercept versus 4. 1 months (95 % CI, 3. 5 to 4. 3 months) for placebo (HR, 0. 82 ; 95 % CI, 0. 72 to 0. 94 ; P =. 0035) ; overall response rate was 23. 3 % of evaluable patients (95 % CI, 19. 1 % to 27. 4 %) in the (ziv -) aflibercept arm versus 8. 9 % (95 % CI, 6. 1 % to 11. 6 % ; P <. 001) in the placebo arm.